133 related articles for article (PubMed ID: 37848029)
21. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus.
Zhu QY; Shan S; Yu J; Peng SY; Sun C; Zuo Y; Zhong LY; Yan SM; Zhang X; Yang Z; Peng YJ; Shi X; Cao SM; Wang X; Zeng MS; Zhang L
Nat Commun; 2021 Nov; 12(1):6624. PubMed ID: 34785638
[TBL] [Abstract][Full Text] [Related]
22. A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments.
Li F; Freed D; Heidecker G; Galli J; Durr E; Wang D
Vaccine; 2022 Jun; 40(26):3638-3646. PubMed ID: 35577627
[TBL] [Abstract][Full Text] [Related]
23. Modulation of Epstein-Barr virus glycoprotein B (gB) fusion activity by the gB cytoplasmic tail domain.
Garcia NJ; Chen J; Longnecker R
mBio; 2013 Jan; 4(1):e00571-12. PubMed ID: 23341550
[TBL] [Abstract][Full Text] [Related]
24. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
25. The Cytoplasmic Tail Domain of Epstein-Barr Virus gH Regulates Membrane Fusion Activity through Altering gH Binding to gp42 and Epithelial Cell Attachment.
Chen J; Jardetzky TS; Longnecker R
mBio; 2016 Nov; 7(6):. PubMed ID: 27935841
[TBL] [Abstract][Full Text] [Related]
26. Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells.
Hong J; Wei D; Zhong L; Wu Q; Chen K; Zhang W; Yang Y; Chen J; Xia N; Zhang X; Chen Y
Front Immunol; 2022; 13():920467. PubMed ID: 35711430
[TBL] [Abstract][Full Text] [Related]
27. Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.
Escalante GM; Mutsvunguma LZ; Muniraju M; Rodriguez E; Ogembo JG
Front Immunol; 2022; 13():867918. PubMed ID: 35493498
[TBL] [Abstract][Full Text] [Related]
28. The Epstein-Barr virus (EBV) glycoprotein B cytoplasmic C-terminal tail domain regulates the energy requirement for EBV-induced membrane fusion.
Chen J; Zhang X; Jardetzky TS; Longnecker R
J Virol; 2014 Oct; 88(20):11686-95. PubMed ID: 25100836
[TBL] [Abstract][Full Text] [Related]
29. The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.
Sun C; Chen XC; Kang YF; Zeng MS
Front Immunol; 2021; 12():677027. PubMed ID: 34168649
[TBL] [Abstract][Full Text] [Related]
30. A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits.
Escalante GM; Foley J; Mutsvunguma LZ; Rodriguez E; Mulama DH; Muniraju M; Ye P; Barasa AK; Ogembo JG
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32268575
[TBL] [Abstract][Full Text] [Related]
31. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing antibodies against EBV gp42 show potent
Wu Q; Zhong L; Wei D; Zhang W; Hong J; Kang Y; Chen K; Huang Y; Zheng Q; Xu M; Zeng MS; Zeng YX; Xia N; Zhao Q; Krummenacher C; Chen Y; Zhang X
Emerg Microbes Infect; 2023 Dec; 12(2):2245920. PubMed ID: 37542379
[TBL] [Abstract][Full Text] [Related]
33. Vaccination against the Epstein-Barr virus.
Rühl J; Leung CS; Münz C
Cell Mol Life Sci; 2020 Nov; 77(21):4315-4324. PubMed ID: 32367191
[TBL] [Abstract][Full Text] [Related]
34. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.
Li W; Chen Q; Lin Q; Lv Y; Feng J; Liu J; Xu W; Chen S; Zhu X; Zhang L
Protein Pept Lett; 2013 Oct; 20(10):1136-43. PubMed ID: 23688153
[TBL] [Abstract][Full Text] [Related]
36. Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model.
Mühe J; Aye PP; Quink C; Eng JY; Engelman K; Reimann KA; Wang F
Cell Rep Med; 2021 Jul; 2(7):100352. PubMed ID: 34337567
[TBL] [Abstract][Full Text] [Related]
37. Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection.
Hong J; Zhong L; Liu L; Wu Q; Zhang W; Chen K; Wei D; Sun H; Zhou X; Zhang X; Kang YF; Huang Y; Chen J; Wang G; Zhou Y; Chen Y; Feng QS; Yu H; Li S; Zeng MS; Zeng YX; Xu M; Zheng Q; Chen Y; Zhang X; Xia N
Cell Rep Med; 2023 Nov; 4(11):101296. PubMed ID: 37992686
[TBL] [Abstract][Full Text] [Related]
38. A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus.
Zhong L; Krummenacher C; Zhang W; Hong J; Feng Q; Zhao Q; Chen Y; Zeng MS; Zeng YX; Xu M; Zhang X
Virol J; 2022 Nov; 19(1):196. PubMed ID: 36424667
[TBL] [Abstract][Full Text] [Related]
39. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells.
Bu W; Kumar A; Board NL; Kim J; Dowdell K; Zhang S; Lei Y; Hostal A; Krogmann T; Wang Y; Pittaluga S; Marcotrigiano J; Cohen JI
Immunity; 2024 Mar; 57(3):559-573.e6. PubMed ID: 38479361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
